Genetic and Non-genetic Factors Associated with Protein Abundance of Flavin-containing Monooxygenase 3 in Human Liver

Meijuan Xu, Deepak Kumar Bhatt, Catherine K. Yeung, Katrina G. Claw, Amarjit S. Chaudhry, Andrea Gaedigk, Robin E. Pearce, Ulrich Broeckel, Roger Gaedigk, Debbie Nickerson, Erin Schuetz, Allan E. Rettie, J. Steven Leeder, Kenneth E. Thummel, Bhagwat Prasad

Department of Pharmaceutics, University of Washington, Seattle, WA, USA. (M.X., D.K.B., K.G.C., K.E.T., and B.P.)

Department of Medicinal Chemistry, University of Washington, Seattle, WA, USA. (C.K.Y. and A.E.R.)

Department of Genome Sciences, University of Washington, Seattle, WA, USA. (D.N.)

Department of Clinical Pharmacology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China. (M.X.)

Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA. (A.S.C and E.S.)

Division of Pediatric Pharmacology and Medical Toxicology, Department of Pediatrics, Children's Mercy Hospitals and Clinics, Kansas City, MO, USA. (A.G., R.E.P., R.G., and J.S. L.)

Section of Genomic Pediatrics, Department of Pediatrics, and Human and Molecular Genetics Center, Medical College of Wisconsin, Milwaukee, WI, USA. (U.B.)
Running title: Interindividual variability in hepatic FMO3 abundance

Corresponding author: Bhagwat Prasad, Ph.D.; Department of Pharmaceutics, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195, Phone: (206) 221-2295, Fax: (206) 543-3204; E-mail: bhagwat@uw.edu

Number of text pages: 19
Number of tables: 2
Number of figures: 6
Number of references: 49
Number of words in Abstract: 228/250
Number of words in Introduction: 586/750
Number of words in Discussion: 1,429/1,500

Abbreviations: ABB, ammonium bicarbonate buffer; BSA, bovine serum albumin; BZD, benzydamine; CYPs, cytochrome P450 enzymes; DTT, dithiothreitol; FAD, flavine-adenine dinucleotide; FMO3, flavin-containing monooxygenase 3; FMOs, flavin-containing monooxygenases; FPKM, fragments per kilobase per million reads; HLM, human liver microsomes; HSA, human serum albumin; HWE, Hardy-Weinberg equilibrium; IAA, iodoacetamide; LC-MS/MS, liquid chromatography-tandem mass spectrometry; LD, linkage disequilibrium; MAF, minor allele frequencies; NADPH, reduced form of nicotinamide-adenine dinucleotide phosphate; PGRN, Pharmacogenomics Research Network; SNPs, single nucleotide polymorphisms.
Abstract

Hepatic flavin-containing monooxygenase 3 (FMO3) metabolizes a broad array of nucleophilic heteroatom (e.g., N or S)-containing xenobiotics (e.g., amphetamine, sulindac, benzydamine, ranitidine, tamoxifen, nicotine, and ethionamide), as well as endogenous compounds (e.g., catecholamine and trimethylamine). To predict the effect of genetic and non-genetic factors on the hepatic metabolism of FMO3 substrates, we quantified FMO3 protein abundance in human liver microsomes (HLM; n=445) by LC-MS/MS proteomics. Genotyping/gene-resequencing, mRNA expression, and functional activity (with benzydamine as a probe substrate) of FMO3 were also performed. FMO3 abundance increased 2.2-fold (13.0±11.4 vs. 28.0±11.8 pmol/mg protein) from neonates to adults. After six years of age, there was no significant difference in FMO3 abundance between children and adults. Female donors exhibited modestly higher mRNA (FPKM values, 139.9±76.9 vs. 105.1±73.1; P<0.001) and protein FMO3 abundance (26.7±12.0 vs. 24.1±12.1 pmol/mg protein; P<0.05) relative to males. Six single nucleotide polymorphisms (SNPs) including rs2064074, rs28363536, rs2266782 (E158K), rs909530 (N285N), rs2266780 (E308G), and rs909531 were associated with significantly decreased protein abundance. FMO3 abundance in individuals homozygous and heterozygous for haplotype 3 (H3), representing variant alleles for all these SNPs (except rs2066534), were 50.8% (P<0.001) and 79.5% (P<0.01), respectively, of those with the reference homozygous haplotype (H1, representing wild-type). In summary, FMO3 protein abundance is significantly associated with age, gender and genotype. These data are important in predicting FMO3 mediated heteroatom-oxidation of xenobiotics and endogenous biomolecules in the human liver.
Introduction

The flavin-containing monooxygenases (FMOs, EC 1.14.13.8) belong to a family of NADPH-, FAD-, and O₂-dependent microsomal enzymes that catalyze the oxidation of a wide variety of nucleophilic heteroatom compounds containing a nitrogen, sulfur, phosphorous, or selenium atom (Krueger and Williams, 2005). Eleven human FMO genes (FMO1 to FMO11P) have been identified to date, but human FMO1 through FMO5 are the only protein coding genes, which have been functionally characterized (Yamazaki and Shimizu, 2013). Members of the FMO gene family display distinct temporal-, tissue-, and species-specific expression patterns (Klick and Hines, 2007). Typical FMO substrates include trimethylamine, catecholamines (Turkanoglu Ozcelik et al., 2013), nicotine (Bloom et al., 2013), imipramine (Wagmann et al., 2016), prothipendyl (Krueger and Williams, 2005), amitriptyline (Krueger and Williams, 2005), phospho-sulindac amide (Xie et al., 2014), benzydamine (BZD) (Taniguchi-Takizawa et al., 2015), ranitidine (Overby et al., 1997), tamoxifen (Parte and Kupfer, 2005), clozapine (Tugnait et al., 1997), diphenhydramine (Cruciani et al., 2014), amphetamine and methamphetamine (Cashman et al., 1999).

FMO3, a protein with 532 amino acids, is the predominant form of the FMO enzyme family expressed in adult human liver (Yamazaki and Shimizu, 2013). Although the FMO3 protein content is high in the liver (Haining et al., 1997; Overby et al., 1997), comparable to cytochrome P450 enzymes (CYPs) (Koukouritaki et al., 2007), the role of FMO3 in xenobiotic or endobiotic metabolism has been often overlooked. The overlapping substrate specificity between FMO3 and CYPs, the thermal instability of the enzyme during in vitro incubation (Cashman, 2008) and the un-availability of selective FMO inhibitors are some of reasons of why contributions of FMO3 to drug biotransformation has not been studied more extensively. Further, many oxidation reactions previously found to be catalyzed by CYPs
were later determined to be catalyzed solely or predominately by FMO3 (e.g., itopride, clozapine and cimetidine) (Cashman et al., 1993; Tugnait et al., 1997; Mushiroda et al., 2000). It has recently been concluded that FMOs are responsible for about 2.2% of all metabolic reactions and about 6% of all the phase I metabolic reactions (Testa et al., 2012). Therefore, FMO3 is considered to be primarily responsible for almost all FMO-mediated reactions of pharmaceutical interest.

Unlike the CYPs, FMO3 is not generally induced or inhibited by xenobiotics (Klick and Hines, 2007) and therefore poses limited drug-drug interaction potential (Cashman, 2008). However, inter-individual differences in FMO3 activity (Overby et al., 1997) could result in significant differences in the FMO3-dependent biotransformation of exogenous and endogenous compounds, leading to unexpected drug reactions or pathological consequences (Koukouritaki et al., 2005). Many single nucleotide polymorphisms (SNPs) are associated with FMO3 function (Mitchell and Smith, 2001; Zhou and Shephard, 2006; Phillips and Shephard, 2008); however, the mechanism is unclear whether these SNPs affect substrate affinity ($K_m$) or FMO3 protein levels. Moreover, some of the $FMO3$ SNPs exhibit linkage disequilibrium (LD) (Cashman and Zhang, 2002); but a systematic classification of haplotypes and diplotypes of FMO3 and their associations with protein activity or abundance have not been established. Although the association of the non-genetic factors, such as age and gender, with FMO3 abundance have been studied previously (Koukouritaki et al., 2002; Shimizu et al., 2011), investigations with multiple samples and with a more precise method for protein quantification are needed.

Therefore, the current study investigated the effect of genetic variations, and non-genetic factors including age, gender and ethnicity on FMO3 hepatic abundance utilizing liquid chromatography-tandem mass spectrometry (LC-MS/MS). The investigation was conducted
in a large cohort of well-characterized pediatric and adult human liver samples (n=445, age range from 0.49 to 87 years).
Materials and Methods

Chemicals and Reagents

Iodoacetamide (IAA), dithiothreitol (DTT), and pierce trypsin protease (MS grade) were purchased from Thermo Fisher Scientific (Rockford, IL). Ammonium bicarbonate buffer (ABB, 98% purity) was purchased from Acros Organics (Geel, Belgium). Chloroform, MS-grade acetonitrile (99.9% purity), methanol and formic acid (≥99.5% purity) were purchased from Fischer Scientific (Fair Lawn, NJ). Human serum albumin (HSA) and bovine serum albumin (BSA) were obtained from Calbiochem (Billerica, MA) and Thermo Fisher Scientific (Rockford, IL), respectively. Synthetic isotopically pure heavy stable isotope-labeled peptides were produced by Thermo Fisher Scientific (Rockford, IL). The purified recombinant FMO3 protein was obtained from Abnova (Walnut, CA; Catalog #: H00002328-P01). NADPH and BZD were purchased from Sigma-Aldrich (St. Louis, MO). BZD N-oxide and dazidamine were obtained as previously described (Yeung et al., 2007).

Human Liver Microsome Samples

Previously isolated human liver microsomes (HLM) (Pearce et al., 2016; Shirasaka et al., 2016) were used in this study. The liver tissue samples for the microsomal preparation were originally received from three liver banks: (1) the University of Washington Human Liver Bank (Seattle, WA, USA) (n=46), (2) Children’s Mercy Kansas City (Kansas City, MO, USA) (n=128), and (3) the Liver Bank at the St. Jude Children’s Research Hospital (Memphis, TN, USA) (n=271). The samples from Children’s Mercy Kansas City were obtained from the University of Maryland Brain and Tissue Bank for Developmental Disorders and the Liver Tissue Cell Distribution System. Additional details on the selection, procurement and storage information of the livers and investigators blinding for sample analyses have been described.
previously (Prasad et al., 2014; Shirasaka et al., 2016; Boberg et al., 2017; Tanner et al., 2017). Age, gender, and ethnicity were known for >95, 98 and 87% of the liver donors, respectively (Supplementary Table 1). The age range for donors was from 0-87 years (mean±SD: 30±24 years). Of the donors with known gender, 61.2% were male. The panel of samples consists of 79.1% Caucasian, 5.8% African American, 0.9% Hispanic, 0.2% Native American, 0.2% Pacific Islander and 12.6% unknown ethnicity donors. Cause of death, medications used, and liver pathology were known for less than 50% of donors; whereas smoking status was unknown for >88% of donors and therefore these factors were not assessed as a predictor of FMO3 phenotypes in the present study. The collection and use of these tissues for research purposes was approved by the human subjects Institutional Review Boards of the University of Washington (Seattle, WA) and the St. Jude Children’s Research Hospital (Memphis, TN), and the Pediatric Institutional Review Board of Children’s Mercy Kansas City (Kansas City, MO).

**FMO3 Protein Quantification**

FMO3 protein quantification was carried out using a validated LC-MS/MS proteomics method. Two surrogate peptides were selected for FMO3 protein quantification and corresponding heavy peptides containing terminal labeled $^{13}\text{C}_6,^{15}\text{N}_4$-arginine and $^{13}\text{C}_6,^{15}\text{N}_2$-lysine residues were used as internal standards. VAIIGAVGVSGLASIR was used as the quantifier and NNLPTAISDLYWK was used as the qualifier (Supplementary Fig. 1). HLM samples were diluted to 2 mg/mL, and 80 μL (160 μg) microsomal protein (or purified FMO3 protein as calibrator) were digested as described previously (Boberg et al., 2017) with minor modifications. Briefly, microsomal protein and 10 μL of HSA (10 mg/mL) and/or 10 μL of BSA (0.2 mg/ml) were denatured and reduced with 10 μL of 250 mM DTT and 40 μL of
ABB buffer (100 mM) at 95°C for 10 min with gentle shaking at 300 rpm. After cooling to
the room temperature for 10 minutes, the denatured protein was alkylated by the addition of
20 µL of 500 mM IAA; the reaction was carried out in the dark for 30 minutes. Ice-cold
methanol (500 µL), chloroform (100 µL) and water (400 µL) were added to each sample.
After vortex-mixing and centrifugation at 16,000 × g (4°C) for 5 minutes, the upper and
lower layers were removed using vacuum suction and the pellets were dried at room
temperature for 10 minutes. The pellets were then washed with 500 µL ice-cold methanol and
subjected to centrifugation at 8000 × g (4°C) for 5 minutes. After the supernatant was
removed, the pellets were dried at room temperature for 30 minutes and re-suspended in 60
µL ABB buffer (50 mM, pH 7.8). Subsequently, the protein pellets were digested by adding
20 µL of trypsin (protein: trypsin ratio, approximately 80:1) and incubating at 37°C for 16
hours. The reaction was quenched by the addition of 20 µL of peptide internal standard
cocktail (prepared in 80% acetonitrile in water containing 0.5% formic acid) and 10 µL 80%
aetonitrile in water containing 0.5% formic acid. The samples were vortex mixed and
subjected to centrifugation at 4000 × g for 5 min and the supernatants were collected in
LC-MS vials. The calibration curve standards ranged from 3.99 to 511 fmol (on-column
amount based on the protein calibrator) were generated by serial diluting of recombinant
FMO3 protein standard in phosphate buffer (50 mM Kpi, 0.25 M sucrose, 10 mM EDTA, pH
7.4) and processed similar to HLM sample. Quantification was performed using a
triple-quadrupole MS instrument (Sciex Triple Quad™ 6500, Ontario, Canada) in ESI
positive ionization mode coupled to an Acquity UPLC, I-class (Waters Technologies, Milford,
MA). 5 µL of the trypsin digest was injected onto the column (ACQUITY UPLC HSS T3 1.8
µm, C18 100A; 100 × 2.1 mm, Waters, Milford, MA). Surrogate light and heavy (internal
standards) peptides were monitored using instrument parameters provided in Supplementary
Table 2. The LC-MS/MS data were processed using Analyst 1.6.2 version software (PE Sciex, Ontario, Canada).

**FMO3 mRNA Quantification**

FMO3 mRNA expression was only quantified in a subset of unprocessed liver tissue samples (n=214, Supplementary Table 1). Details of the RNA-seq procedures including RNA isolation, truSeq stranded mRNA preparation, and read processing and analysis pipeline were described previously (Tanner et al., 2017). The transcript levels of mRNA are displayed in FPKM (fragments per kilobase per million reads) values.

**FMO3 Enzyme Activity Assay**

FMO3 enzyme activity was performed on a limited number of HLM samples prepared from fresh liver tissues (donor age range from 9 to 68 years; mean±SD, 40.1±17.9 years, n=37, Supplementary Table 1) due to the potential instability of the protein to freeze-thaw cycles (Cashman, 2008). The activity was determined by quantifying the rate of BZD N-oxidation (Stormer et al., 2000). The assay conditions include: 0.2 mg/mL HLM protein, 0.1 M phosphate buffer (pH 7.4), 50 μM BZD, 0.5 mM NADPH, and water to a final volume of 250 μL. All reactions were performed in triplicate. Following a pre-incubation of 3 min at 37 °C, the reaction was initiated with the addition of substrate and allowed to continue with gentle agitation (70 rpm) for 20 min. The reaction was quenched with an equal volume of acetonitrile containing 0.1 mg/mL dazidamine (internal standard). Incubations were then placed on ice for 5 minutes to allow for full protein precipitation prior to centrifugation (14,000 rpm × 5 min). The supernatant was analyzed by an optimized HPLC method as reported previously (Yeung and Rettie, 2006). Briefly, chromatographic separations of BZD,
BZD N-oxide, and dazidamine were performed on an Agilent Hypersil ODS C\textsubscript{18} column (4.0 × 250 mm, 5 μm). The mobile phase consisted of methanol:acetonitrile:water:29% NH\textsubscript{4}OH (50:40:10:0.05, v/v/v/v, A) and water (B). The mobile phase components were mixed at a fixed ratio of 92%A + 8%B, and a flow rate of 1.0 mL/min was used. The effluent was monitored fluorometrically with an excitation wavelength of 307 nm and an emission wavelength of 377 nm. Approximate retention times for BZD N-oxide, dazidamine, and BZD were 4, 6 and 8 min, respectively.

**FMO3 Gene-resequencing, Genotyping and Haplotypes Determination**

Two different approaches, gene-resequencing or genotyping, were used for genetic characterization of the liver donors because these data were generated in two different institutes (Supplementary Table 1). FMO3 gene-resequencing was performed using the PGRN-Seq platform, a targeted sequencing approach, for the University of Washington and St. Jude Liver Bank samples, as discussed elsewhere (Gordon et al., 2016). DNA of the tissues provided by Children’s Mercy were genotyped on the PharmacoScan (Affymetrix, Santa Clara, CA, USA). LD analysis of FMO3 variants and inferred haplotypes were determined using Haploview 4.2 (Cambridge, MA, USA).

**Data Analysis**

We used a robust strategy to ensure optimum reproducibility when quantifying FMO3 proteins. For example, ion suppression was addressed by using heavy peptide internal standards. BSA was used as exogenous protein internal standards, which was added to each sample as a fixed quantity before methanol-chloroform-water extraction and trypsin digestion. Addition of BSA addresses the variability introduced during the pre-digestion processing.
steps such as i) protein loss during methanol-chloroform-water extraction and ii) sample-to-sample trypsin digestion artifacts. To address inter-batch variability, we processed three sets of pooled representative HLM samples each day, which served as quality controls across the entire study. In total, a three-step data normalization approach was used; first, average of detectable light peak areas for specific peptide daughter fragments were divided by average of detectable heavy peak areas. For example, we used ratio of average of three fragments of VAIIGAGVSGLASIR (light) and average of two fragments of VAIIGAVGAGVSGLASIR\^{13}C\_6,^{15}N\_4\]R (heavy) for FMO3 quantification. More fragments of the light peptide were used in this case because the dynamic range for analyte peptide (i.e., light) was unpredictable as compared to the heavy internal standard peptide. Next, this ratio was further divided by the BSA light/heavy area ratio. Finally, for each day, these data were further normalized by mean values of the quality control values run with individual batch to adjust for any inter-day variability.

The samples were classified based on the following age-categories: neonatal plus infancy (0 to 364 days), toddler/early childhood (1 year to <6 years), middle childhood (6 to <12 years), adolescence (12 to 18 years) and adulthood (>18 years).

Statistical analyses were performed using GraphPad Prism 5 (La Jolla, CA, USA) and Microsoft Excel (Version 14, Redmond, WA, USA). The protein abundance, mRNA expression levels and activity data were non-normally distributed, and therefore non-parametric tests were used to test age-, gender-, ethnicity- or genotype-dependence. To compare two groups (e.g., male vs. female), the Mann-Whitney test was used. The Kruskal-Wallis test followed by Dunn’s multiple comparison test were used to perform the age-dependent data analysis and determine associations between FMO3 genotype and mRNA expression levels, FMO3 protein abundance, and the enzyme activity. For correlation analysis,
the non-parametric Spearman regression test was used.

$$F = \left( \frac{Adult_{max} - F_{birth}}{Age_{50}^{n} + Age^{n}} \right) \times Age^{n} + F_{birth} \quad \text{(Equation 1)}$$

A nonlinear regression equation (Equation 1) was used to fit the ontogeny data, as described previously (Boberg et al., 2017), where $Adult_{max}$ is the maximum average relative protein abundance, $Age$ is the age in years of the subject at the time of sample collection, $Age_{50}$ is the age in years at which half-maximum adult protein abundance is obtained, $F$ is the fractional protein abundance in adult samples, $F_{birth}$ is the fractional protein abundance (of adult) at birth, and $n$ is the exponential factor.

The number of variants was directly counted. Hardy-Weinberg equilibrium (HWE) was determined by comparing the variant frequencies with the expected values using a contingency table chi-square statistic with Yates’ correction. The numbers of haplotype, statistics D, D’ and LD were estimated by Haploview 4.2 (Cambridge, MA, USA) software. A $P$-value below 0.05 was considered to be statistically significant.
Results

Absolute Quantification of Human Hepatic FMO3 based on LC-MS/MS and Correlation to mRNA and Activity data

The calibration curves for FMO3 (3.99 to 511 fmol, on-column) demonstrated good linearity ($r^2>0.99$, Supplementary Fig. 2). The lower limit of quantification for the FMO3 protein standard in the trypsin digestion buffer was 3.99 fmol (on-column). The intra-day precision (% coefficient of variance) of the analytical method, based on pooled quality control samples, was within 25%.

The average human liver FMO3 protein concentration in HLM samples ($n=445$) was 25.1±12.0 pmol/mg microsomal protein with 124-fold interindividual variation (0.76-94.5 pmol/mg microsomal protein). Furthermore, FMO3 protein abundance was positively correlated with BZD N-oxidation activity ($r=0.73$, $P<0.001$, Fig.1). However, the correlation between FMO3 mRNA and protein abundance was poor ($r=0.19$, $P>0.05$) (data not shown).

Association of Non-genetic Factors with Human Hepatic FMO3 Abundance

Age was positively associated with FMO3 protein abundance. Stratifying by age as a categorical variable, the FMO3 protein abundance was 1.9-fold ($P < 0.001$) higher in adults compared to neonates (0-1 year) (Fig. 2A). Similarly, FMO3 abundance in neonatal liver was significantly lower compared to that observed in middle childhood (6-12 years, $P < 0.01$) and adolescence (12-18 years, $P < 0.001$). FMO3 protein levels were lower in infants (1-6 years, $P<0.001$) compared to adults. Age vs. FMO3 abundance with age as a continuous variable is shown in Fig. 2B. Nonlinear regression of the HLM protein abundance data revealed that the FMO3 protein was 50% of the values observed in adults at the age of approximately 10 months. The effect of age on FMO3 protein abundance was independent of the genotype
(Figs. 2C and 2D) as discussed below.

Female liver donors exhibited modestly higher FMO3 protein (26.7±12.0 vs. 24.1±12.1 pmol/mg protein, \( P<0.05 \), Fig. 3A) and mRNA levels (FPKM values, 139.9±76.9 vs. 105.1±73.1, \( P<0.001 \), Fig. 3B) as compared to males. The gender difference in both protein and mRNA levels were consistent even when pediatric samples below 6 years of age were excluded from the analysis (Supplementary Fig. 3). However, no significant difference in FMO3 activity was observed between female and male samples perhaps due to the small number of samples (data not shown).

No significant difference of FMO3 protein abundance was observed among Caucasians (25.4±12.4 pmol/mg protein, \( n=352 \)) and African Americans (22.1±14.1 pmol/mg protein, \( n=30 \)).

**Association of Genetic Factors with Human Hepatic FMO3 Abundance**

Gene re-sequencing of the 285 tissue samples (263 Caucasians, 2 African Americans, 1 Asian, and 19 unknown) from University of Washington and St. Jude Children’s Research Hospital identified 21 variants in *FMO3*. Eleven of these variants were within the coding sequence and ten were intronic variants (Table 1). Out of these 21 variants identified, 11 variants (rs2064074, rs1800822, rs72549326, rs2266782, rs2066534, rs1736557, rs909530, rs61753344, rs2266780, rs909531 and rs72549334) have been reported previously in the literature, and an additional seven variants (rs4140653, rs28363536, rs143661234, rs75904274, rs79952472, rs373775407 and rs373403267) were found in the Single Nucleotide Polymorphism Database (dbSNP, https://www.ncbi.nlm.nih.gov/snp/). However, no reports for three of the variants could be found. The minor allele frequencies (MAF) of these variants are shown in Table 1.
HLM samples (with donor age over six years) were grouped according to the results of FMO3 gene-resequencing data. Six SNPs were associated with decreased FMO3 protein abundance (Fig. 4). These SNPs include three missense (rs2266782, E158K; rs909530, N285N; and rs2266780, E308G) and three intronic (rs2064074, rs28363536, and rs909531) SNPs. However, there was no association between FMO3 mRNA expression and BZD N-oxidase activity among those SNPs that showed a correlation with protein abundance (Supplementary Figs. 4 and 5).

To avoid false positive associations between these variants and FMO3 levels, LD analysis was subsequently performed. All SNPs within FMO3 were in HWE (P>0.05, Table 1). Haplotype blocks and haplotypes were inferred based on the allele frequencies of the SNPs by using Haploview. In total, two haplotype blocks (Fig. 5) and six haplotypes, which occurred at a frequency greater than 1% accounting for more than 98.5% of the total chromosomes examined, were identified (Table 2). Six SNPs (rs2266782, rs909530, rs2266780, rs2064074, rs28363536, and rs909531), which were associated with FMO3 abundance, were found in strong LD (D'>0.975) with each other, except between rs2266782 and rs909530, where a median LD (D'=0.632) was observed. Regression coefficients ($r^2$) of these pair-wise SNPs indicated that rs28363536, rs2266780 (E308G) and rs909531 tag the same haplotype ($r^2>0.97$); rs2266782 (E158K) was associated with rs22064074 ($r^2=0.78$); and rs2266780 (E308G) was associated with rs909530 (N285N) ($r^2=0.71$). Diplotype-dependent protein abundance of FMO3 was observed after excluding the effect of ontogeny. Samples (with donor age over 6 years) harboring the H3 haplotype, which consist of six SNPs, had up to 50% lower FMO3 protein levels as compared to the reference haplotype H1 (Fig. 6). The association between H3 haplotype and FMO3 activity could not be investigated because of the smaller number of samples and higher variability (data not
Additionally, genotype analysis of the pediatric samples from Children’s Mercy Kansas City (n=128) detected eight variants in *FMO3* (seven exonic and one intronic; Supplementary Table 3). Since genotyping was performed on a different platform, the comprehensive Haploview analysis described above for the adult samples could not be performed on the pediatric samples. However, consistent with the data described above, two SNPs, rs2266782 (E158K) and rs2266780 (E308G), showed associations with protein abundance (Supplementary Figs. 6A and 6B). No associations were detected for other variants, which is possibly due to the low variant frequencies and/or confounding age-related variability. Furthermore, the impact of haplotype E158K-E308G on FMO3 protein abundance was shown in Supplementary Fig. 6C. Considering the impact of allelic variants on FMO3 abundance, the association between age and human hepatic FMO3 protein was reanalyzed. Age-dependent protein abundance of FMO3 was still observed after excluding the samples harboring the homozygous E158K-G308G. The FMO3 protein abundance was 2.2-fold ($P < 0.001$) higher in adults compared to neonates (0-1 year) (Fig. 2C). After six years of age, there was no significant difference in FMO3 abundance between children and adults. FMO3 protein was 50% of the values observed in adults by approximately 15 months based on the reanalysis of the data (Fig. 2D).
Discussion

In the present study, several genetic and non-genetic factors that contribute to variation in human hepatic FMO3 were identified in a large cohort of samples (n=445). Although FMO quantification in the human livers has been accomplished by Western blotting and LC-MS/MS in previous studies (Overby et al., 1997; Chen et al., 2016), the sample sizes were small (n=5-10) in these studies and the associations of genetic factors as well as the interplay of ontogeny and genotype were not investigated. Consistent with the reported data based on the immunoblotting method (Koukouritaki et al., 2002; Shimizu et al., 2011), an age-dependent increase in FMO3 protein levels was also observed in this study (Fig. 2). Koukouritaki et al. found that FMO3 expression increased 4.5-fold between three weeks and 10 months (1.1 pmol/mg protein to 4.7 pmol/mg protein), with another approximate 3-fold between 10 months and 11 years (4.7 pmol/mg protein to 12.7 pmol/mg protein) (Koukouritaki et al., 2002). Between 11 and 18 years of life, there was a third significant increase in mean expression levels (12.7 pmol/mg protein to 26.9 pmol/mg protein) (Koukouritaki et al., 2002). In the present study, only a 2-fold increase in mean FMO3 abundance was observed between infancy (0-1 year) and middle childhood (6-12 years), and no significant increase was found in the donors over 6 years of age. However, the hepatic FMO3 levels found in both studies were comparable (24.2 vs. 26.9 pmol/mg protein) in adolescence. Differences in sensitivity at lower concentrations between Western blotting and LC-MS/MS methods, age classification criteria, quality of samples and data analysis (3-17% of samples in each age group were excluded in the study by Koukouritaki et al) may explain, at least in part, the differing observations between studies.

An association between gender and hepatic FMO3 levels has not been revealed in previous reports (Cherrington et al., 1998; Koukouritaki et al., 2002). In this study, we
observed a modest, statistically significant (but perhaps not clinically relevant) gender difference in FMO3 mRNA and protein abundances (Fig. 3), perhaps because of the larger number of samples tested and increase statistical power. Previous studies have shown that female mouse livers contain higher levels of FMO3 mRNA levels (80-fold) than those in male liver samples (Janmohamed et al., 2004). This may be due to the modulating effects of testosterone on FMO3 expression; testosterone but not 17-estradiol suppresses mouse FMOs hepatic activity (dimethylaniline N-oxidation) (Duffel et al., 1981). Following castration, hepatic FMO activity (methimazole oxidation) increased significantly and serum testosterone levels decreased; however, administration of physiological levels of testosterone to castrated animals returned FMO activity (Falls et al., 1997). However, there is little evidence for sex hormone-regulation of the FMO3 abundance in human liver. While gender difference was apparently observed for FMO3 mRNA as well as the protein expression, the regression analysis indicated lack of correlation between FMO3 mRNA and protein expression, in consistent with the previous study (Overby et al., 1997). The latter indicates that FMO3 mRNA is not a good surrogate of its protein abundance. This lack of association could be a result of different mechanisms of mRNA and protein regulation (Liu et al., 2016) or mRNA instability in the frozen-thawing procedure of the samples (Botling et al., 2009).

More than 300 SNPs have been reported for FMO3 (http://www.ncbi.nlm.nih.gov). Most are rare and over 40 of these polymorphisms have been linked to altered FMO3 function and symptomatic trimethylaminuria (also referred as “fish-like odor syndrome”) (Yeung et al., 2007). FMO3 variants have also been associated with higher risks of sudden infant death syndrome (Poetsch et al., 2010) and hypertension-related ischemic stroke (Turkanoglu Ozcelik et al., 2013), altered cigarette consumption (Bloom et al., 2013), and increased efficacy of sulindac to prevent familial adenomatous polyposis (Hisamuddin et al., 2004).
vitro FMO3 activity studies investigating the effects of nonsynonymous variants or some haplotypes, such as E158K, E132H, E308G, E132H-E158K, E158K-E308G, on kinetic parameters revealed that $V_{max}$ values of the variant forms are lower than the reference allele (Lattard et al., 2003; Yamazaki and Shimizu, 2013); but changes in $K_m$ are substrate-dependent (Lattard et al., 2003; Yeung et al., 2007). These results indicate that the effects of nonsynonymous variants on FMO3 substrate affinity may be substrate-dependent, but their effects on FMO3 abundance are consistent. However, direct evidence of the association between genetic variation and FMO3 protein abundance has never been studied.

In the present study, six SNPs were identified that are associated with decreased FMO3 protein expression. Individuals homozygous for the missense variant allele E158K (rs2266782) was associated with significantly lower FMO3 protein levels (Fig. 4), which was consistent with the 65% reduced FMO3 catalytic efficiency ($V_{max}/K_m$) in vitro towards multiple substrates such as methimazole, trimethylamine and 10-(N,N-dimethylaminopentyl)-2-(trifluoromethyl) -phenothiazine) (Lattard et al., 2003). Similarly, a positive association between protein abundance and activity was observed for another amino acid change, E308G, caused by rs2266780 (Lattard et al., 2003). Two other variants, P153L (rs72549326) and E305X (rs61753344), previously shown to have no functional activity (Treacy et al., 1998; Yeung et al., 2007), could not be tested in this study because of the lack of sufficient samples. Albeit, the FMO3 abundance was lower (11.8 and 7.8 vs. 26.4 pmol/mg protein for P153L and E305X vs. reference allele, respectively) in the single heterozygous sample present in our cohort. Similarly, another function-unchanging missense SNP, V257M (rs1736557) (Treacy et al., 1998), showed no relation to FMO3 protein levels in this study. Several mechanisms could potentially explain decreased protein levels as a result of inherited alterations in encoded amino acid sequence, but the mechanism has most often involved accelerated
degradation of the variant allozyme, which is typically via an ubiquitin-proteasome-mediated pathway (Weinshilboum and Wang, 2004). Furthermore, one synonymous SNP (N285N, rs2266780) and three intronic variants (rs2064074, rs28363536, and rs909531) were also associated with the decreased FMO3 protein abundance (Fig. 4). Although synonymous SNPs and variants in intronic regions may also contribute to changes in protein abundance by impacting splicing, translation fidelity, mRNA stability and protein folding (Sauna and Kimchi-Sarfaty, 2011), no correlation between FMO3 function and these SNPs has been reported. Three samples showed relatively high FMO3 protein levels but very small BZD N-oxidation activity (Fig. 1). The potential mechanism of the disconnection between FMO3 protein levels and activity might be the instability of FMO3 protein or unique functional variant not investigated in the present study.

LD analysis data showed that SNP rs2266780 (N285N), rs2064074, rs28363536, and rs909531 is perhaps related to E308G and/or E158K, indicating that the suppressive impacts of these four SNPs on FMO3 protein abundance may be from one or both of the exonic SNPs. Moreover, consistent with previous studies which reported that $V_{max}$ of FMO3 were Wild-type > E158K ≈ E308G > E158K-E308G (Lattard et al., 2003; Krueger and Williams, 2005), the FMO3 protein abundance of a donor homozygous for haplotype E158K-E308G, was found to be significantly lower than the reference allele in this study (Fig. 6 and Supplementary Fig. 6). This is the first direct evidence that the decreased FMO3 protein abundance in liver tissues from donors harboring these SNPs (E158K and E308g variants) is one of the possible reasons for a significant reduction in FMO3 activity.

There were a number of limitations in this study. For instance, although we determined protein levels of FMO3 in 445 samples, we were only able to access 37 fresh samples and only one typical substrate was used to measure enzyme activity; this sample size was
insufficient to draw definite conclusions regarding the associations of genotype with FMO3 activity using HLM samples. The samples used for mRNA expression (n=214), gene-resequencing (n=285), and genotype determination (n=129) were also limited due to the lack of available liver tissue from all the donors. Thus, interplay of ontogeny and genotype on FMO3 abundance could not be fully evaluated in this study. Finally, health condition and smoking status were unknown for most of the donors, suggesting that the inter-individual differences of FMO3 protein abundance and mRNA levels may also come from other potential factors.

In summary, hepatic levels of FMO3 (25.1±12.0 pmol/mg protein) demonstrated marked inter-individual variation (124 fold) in a large panel of HLM samples (n=445). Age and genetic variation were the two main sources for this variation. Our results combined with reported differences in intrinsic catalytic activity of the different FMO3 variants may be useful in the derivation of scaling factors that may be applied to predict age- or genotype-dependent hepatic clearance of FMO3 substrates via PBPK modeling and simulations. Moreover, these data may be hypothesis generating for future clinical studies designed to predict the effects of FMO3 haplotype on the pharmacokinetics and pharmacodynamics of FMO3 substrates.
Acknowledgement

We would like to thank Prachi Jha and Dr. Aanchal Mehrotra for assistance with LC-MS/MS sample analysis.

Authorship contributions

Participated in research design: Meijuan Xu, Deepak Kumar Bhatt, Catherine K. Yeung, Bhagwat Prasad

Conducted experiments: Meijuan Xu, Deepak Kumar Bhatt, Katrina G. Claw, Catherine K. Yeung, Ulrich Broeckel, Roger Gaedigk, Bhagwat Prasad

Contributed reagents or analytic tools: Kenneth E. Thummel, J. Steven Leeder, Allan E. Rettie, Amarjit S. Chaudhry, Andrea Gaedigk, Robin E. Pearce, Debbie Nickerson, Erin Schuetz,

Performed data analysis: Meijuan Xu, Deepak Kumar Bhatt, Katrina G. Claw, Catherine K. Yeung, Amarjit S. Chaudhry, Andrea Gaedigk and Bhagwat Prasad

Wrote or contributed to the writing of the manuscript: Meijuan Xu, Katrina G. Claw, Catherine K. Yeung, Deepak Kumar Bhatt, Amarjit S. Chaudhry, Andrea Gaedigk, Robin E. Pearce, Debbie Nickerson, Erin Schuetz, Allan E. Rettie, J. Steven Leeder, Kenneth E. Thummel, Bhagwat Prasad
Reference


Chen Y, Zane NR, Thakker DR and Wang MZ (2016) Quantification of Flavin-containing
Monooxygenases 1, 3, and 5 in Human Liver Microsomes by UPLC-MRM-Based Targeted Quantitative Proteomics and Its Application to the Study of Ontogeny. *Drug Metab Dispos* **44**:975-983.


Footnotes:

This work was primarily supported by the National Institutes of Health Grant (NIH; R01 HD081299-02). Liver sample procurement, sub-cellular isolation, transcript and genotyping data analysis for the UW and SJ samples were supported by the NIH grants, U01 GM092676 and P01 GM116691. The National Institute of Child Health and Human Development Brain and Tissue Bank for Developmental Disorders at the University of Maryland is funded by the NIH contract HHSN275200900011C, reference number, N01-HD-9-0011 and the Liver Tissue Cell Distribution System is funded by NIH contract number N01-DK-7-0004/HHSN267200700004C. Meijuan Xu was supported by the China Clinical Evaluation Research Institute (Grant No. KK11-1).

M.X. and D.K.B. contributed equally to this work.
**Figure legend**

**Fig. 1** Association between FMO3 protein abundance (pmol/mg protein) and BZD $N$-oxidation activity in human liver microsomes (n=37).

**Fig. 2** Association between age and FMO3 protein levels in human liver without (A and B) and with (C and D) considering interplay with diplotype E158K-E308G. A and C represent categorical data and, B and D show continuous data. Dots indicate individual protein abundance and the mean and S.D. are presented as the horizontal line and error bar. The Kruskal-Wallis test followed by Dunn’s multiple comparison test were used to compare protein levels; ** and *** indicate $P$ values of <0.01 and <0.001, respectively.

**Fig. 3** Association between gender and FMO3 protein (A) and mRNA (B) levels in human liver. Dot plots are displayed with mean abundance as the horizontal line, and the error bar displays S.D. with individual maximum and minimum values shown in the dot plot. The Mann-Whitney test was used to compare FMO3 levels; * and *** indicate $P$ values of <0.05 and <0.001, respectively.

**Fig. 4** Association between genetic variation and FMO3 protein levels in human liver microsomes (with donor age over six years). A-F represent individual SNPs, i.e., rs2064074, rs28363536, rs2266782 (E158K), rs909530 (N285N), rs2266780 (E308G), and rs909531, respectively. Dots indicate individual protein abundance and the mean and S.D. are presented as the horizontal line and error bar. The Kruskal-Wallis test followed by Dunn’s multiple comparison test were used to compare protein levels; *, ** and *** indicate $P$ values of <0.05, <0.01 and <0.001, respectively.
**Fig. 5** A schematic representation of human *FMO3* gene structure and linkage disequilibrium (LD) generated by Haploview 4.2. The HW *P*-value cutoff and minimum MAF were 0.01 and 0.02, respectively.

**Fig. 6** Association between *FMO3* diplotypes and FMO3 protein levels in human liver (with donor age over six years). Only those diplotypes that show statistical significance in FMO3 protein abundance are presented. Dots indicate individual protein abundance and the mean and S.D. are presented as the horizontal line and error bar. The Kruskal-Wallis test followed by Dunn’s multiple comparison test were used to compare protein levels; *, ** and *** indicate *P* values of <0.05, <0.01 and <0.001, respectively.
<table>
<thead>
<tr>
<th>Variants No.</th>
<th>Chromosome Position</th>
<th>Nucleotide Change</th>
<th>Location</th>
<th>Amino Acid Change</th>
<th>rs Number</th>
<th>HW P value</th>
<th>MAF</th>
<th>FMO3 function</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>171061989</td>
<td>C&gt;T</td>
<td>Intron 2</td>
<td>rs4140653</td>
<td>0.6354</td>
<td>0.037</td>
<td></td>
<td></td>
<td>(Koukouritaki et al., 2005)</td>
</tr>
<tr>
<td>2</td>
<td>171061990</td>
<td>A&gt;G</td>
<td>Intron 2</td>
<td>rs2064074</td>
<td>0.1809</td>
<td>0.47</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>171072862</td>
<td>G&gt;T</td>
<td>Intron 2</td>
<td>rs28363536</td>
<td>0.3712</td>
<td>0.198</td>
<td></td>
<td></td>
<td>(Koukouritaki et al., 2005)</td>
</tr>
<tr>
<td>4</td>
<td>171076813</td>
<td>T&gt;G</td>
<td>Exon 3</td>
<td>rs1800822</td>
<td>1</td>
<td>0.002</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>171076935</td>
<td>C&gt;T</td>
<td>Exon 4</td>
<td>S147S</td>
<td>rs1800822</td>
<td>1</td>
<td>0.058</td>
<td></td>
<td>(Koukouritaki et al., 2005; Yamazaki and Shimizu, 2013)</td>
</tr>
<tr>
<td>6</td>
<td>171076952</td>
<td>C&gt;T</td>
<td>Exon 4</td>
<td>P153L</td>
<td>rs72549326</td>
<td>1</td>
<td>0.002</td>
<td>Inactive</td>
<td>(Treacy et al., 1998; Yeung et al., 2007)</td>
</tr>
<tr>
<td>7</td>
<td>171076966</td>
<td>G&gt;A</td>
<td>Exon 4</td>
<td>E158K</td>
<td>rs2266782</td>
<td>0.1308</td>
<td>0.412</td>
<td>Decreased</td>
<td>(Furnes et al., 2003; Koukouritaki et al., 2005; Yeung et al., 2007; Yamazaki and Shimizu, 2013)</td>
</tr>
<tr>
<td>8</td>
<td>171077038</td>
<td>GTCT&gt;G</td>
<td>Intron 4</td>
<td>rs143661234</td>
<td>1</td>
<td>0.058</td>
<td></td>
<td></td>
<td>(Koukouritaki et al., 2005)</td>
</tr>
<tr>
<td>9</td>
<td>171077274</td>
<td>G&gt;T</td>
<td>Exon 5</td>
<td>rs75904274</td>
<td>1</td>
<td>0.016</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>171077372</td>
<td>C&gt;G</td>
<td>Intron 5</td>
<td>rs2066534</td>
<td>0.9376</td>
<td>0.209</td>
<td></td>
<td></td>
<td>(Koukouritaki et al., 2005)</td>
</tr>
<tr>
<td>11</td>
<td>171077393</td>
<td>C&gt;A</td>
<td>Intron 5</td>
<td>rs79952472</td>
<td>1</td>
<td>0.002</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>171079971</td>
<td>G&gt;A</td>
<td>Exon 6</td>
<td>V220V</td>
<td>rs373775407</td>
<td>1</td>
<td>0.002</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>171080080</td>
<td>G&gt;A</td>
<td>Exon 6</td>
<td>V257M</td>
<td>rs1736557</td>
<td>1</td>
<td>0.081</td>
<td>No change</td>
<td>(Furnes et al., 2003; Koukouritaki et al., 2005; Yeung et al., 2007; Yamazaki and Shimizu, 2013)</td>
</tr>
<tr>
<td>14</td>
<td>171083128</td>
<td>GTC&gt;G</td>
<td>Intron 6</td>
<td>rs143661234</td>
<td>1</td>
<td>0.058</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>171083174</td>
<td>C&gt;T</td>
<td>Exon 7</td>
<td>N285N</td>
<td>rs909530</td>
<td>1</td>
<td>0.261</td>
<td></td>
<td>(Furnes et al., 2003; Koukouritaki et al., 2005)</td>
</tr>
<tr>
<td>16</td>
<td>171083208</td>
<td>G&gt;T</td>
<td>Exon 7</td>
<td>rs143661234</td>
<td>1</td>
<td>0.002</td>
<td></td>
<td></td>
<td>(Treacy et al., 1998)</td>
</tr>
<tr>
<td>17</td>
<td>171083232</td>
<td>G&gt;T</td>
<td>Exon 7</td>
<td>rs61753344</td>
<td>1</td>
<td>0.002</td>
<td></td>
<td>Inactive</td>
<td>(Koukouritaki et al., 2005; Yeung et al., 2007; Yamazaki and Shimizu, 2013)</td>
</tr>
<tr>
<td>18</td>
<td>171083242</td>
<td>A&gt;G</td>
<td>Exon 7</td>
<td>rs2266780</td>
<td>0.3712</td>
<td>0.198</td>
<td></td>
<td>Decreased</td>
<td>(Koukouritaki et al., 2005; Yeung et al., 2007)</td>
</tr>
<tr>
<td>19</td>
<td>171083537</td>
<td>T&gt;C</td>
<td>Intron 7</td>
<td>rs909531</td>
<td>0.6644</td>
<td>0.209</td>
<td></td>
<td></td>
<td>(Koukouritaki et al., 2005)</td>
</tr>
<tr>
<td>20</td>
<td>171083540</td>
<td>A&gt;G</td>
<td>Intron 7</td>
<td>rs373403267</td>
<td>1</td>
<td>0.002</td>
<td></td>
<td></td>
<td>(Yeung et al., 2007)</td>
</tr>
<tr>
<td>21</td>
<td>171086457</td>
<td>C&gt;T</td>
<td>Exon 9</td>
<td>R492W</td>
<td>rs72549334</td>
<td>1</td>
<td>0.002</td>
<td>Inactive</td>
<td>(Yeung et al., 2007)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Table 2** Haplotype analysis data of *FMO3* in 285 samples

<table>
<thead>
<tr>
<th>Haplotype</th>
<th>Block 1</th>
<th>Block 2</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Block 1</td>
<td>Block 2</td>
<td>Frequency</td>
</tr>
<tr>
<td></td>
<td>(Intron 2)</td>
<td>(E158K)</td>
<td>(Intron 5)</td>
</tr>
<tr>
<td>H1</td>
<td>A</td>
<td>G</td>
<td>G</td>
</tr>
<tr>
<td>H2</td>
<td>G</td>
<td>G</td>
<td>A</td>
</tr>
<tr>
<td>H3</td>
<td>G</td>
<td>T</td>
<td>A</td>
</tr>
<tr>
<td>H4</td>
<td>G</td>
<td>G</td>
<td>G</td>
</tr>
<tr>
<td>H5</td>
<td>G</td>
<td>G</td>
<td>G</td>
</tr>
<tr>
<td>H6</td>
<td>G</td>
<td>G</td>
<td>A</td>
</tr>
</tbody>
</table>

Haplotypes with frequencies ≥ 1%. Haplotype tag SNPs (htSNPs) are identified by an asterisk (*). The wild-type (reference) nucleotides are marked in bold.
Figure 2
Figure 4
Figure 6

FMO3 Abundance (pmol/mg protein)

<table>
<thead>
<tr>
<th></th>
<th>Number (n)</th>
<th>Mean (pmol/mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>H1 Homo</td>
<td>75</td>
<td>31.4</td>
</tr>
<tr>
<td>H2 Homo</td>
<td>10</td>
<td>30.4</td>
</tr>
<tr>
<td>H3 Homo</td>
<td>12</td>
<td>16.0</td>
</tr>
<tr>
<td>H3 Hetero</td>
<td>68</td>
<td>25.0</td>
</tr>
</tbody>
</table>